Evidence map›Paper›PMID 35946346›Full record

ReviewMolecular genetics & genomic medicine2022

Report of two pedigrees with heterozygous HTRA1 variants-related cerebral small vessel disease and literature review.

Hui Zhou, Bin Jiao, Ziyu Ouyang, Qihui Wu, Lu Shen, Liangjuan Fang

Open access · goldAbstract readReview
In one paragraph

Review in Molecular genetics & genomic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Heterozygous Pathogenic and Likely Pathogenic SymptomaticInternational journal of general medicine · 2023
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Hui ZhouDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.ORCID 0000-0001-9551-8141
Bin JiaoDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Ziyu OuyangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Qihui WuTranslational Research Institute of Brain and Brain-Like Intelligence, Shanghai Fourth People's Hospital affiliated to Tongji University School of Medicine, Shanghai, China.
Lu ShenDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Liangjuan FangDepartment of Neurology, Xiangya Hospital, Central South University, Changsha, China.
Central South University · CNTongji University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundBiallelic HTRA1 pathogenic variants are associated with autosomal recessive cerebral arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL). Recent studies have indicated that heterozygous HTRA1 variants are related to autosomal dominant hereditary cerebral small vessel disease (CSVD). However, few studies have assessed heterozygous HTRA1 carriers or the genotype-phenotype correlation.

methodsThe clinical data of two unrelated Chinese Han families with CSVD were collected. Panel sequencing was used to search for pathogenic genes, Sanger sequencing was used for verification, three-dimensional protein models were constructed, and pathogenicity was analyzed. Published HTRA1-related phenotypes included in PubMed up to September 2021 were extensively reviewed, and the patients' genetic and clinical characteristics were summarized.

resultsWe report a novel heterozygous variant c.920T>C p.L307P in the HTRA1, whose main clinical and neuroimaging phenotypes are stroke and gait disturbance. We report another patient with the previously reported pathogenic variant HTRA1 c.589C>T p.R197X characterized by early cognitive decline. A literature review indicated that compared with CARASIL, HTRA1-related autosomal dominant hereditary CSVD has a later onset age, milder clinical symptoms, fewer extraneurological symptoms, and slower progression, indicating a milder CARASIL phenotype. In addition, HTRA1 heterozygous variants were related to a higher proportion of vascular risk factors (p < .001) and male sex (p = .022).

conclusionThese findings broaden the known mutational spectrum and possible clinical phenotype of HTRA1. Considering the semidominant characteristics of HTRA1-related phenotypes, we recommend that all members of HTRA1 variant families undergo genetic screening and clinical follow-up if carrying pathogenic variants.

Indexed as

Cerebral Small Vessel DiseasesAlopeciaCerebral InfarctionFemaleHeterozygoteHigh-Temperature Requirement A Serine Peptidase 1HumansLeukoencephalopathiesMalePedigreeSpinal DiseasesHigh-Temperature Requirement A Serine Peptidase 1HTRA1 protein, humanAlzheimer's diseaseCARASILcerebral small vessel diseaseheterozygous variantHTRA1

Identifiers

PMID35946346
PMCPMC9544214
OpenAlexW4297826628

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.